ShiraTronics has initiated its RELIEV-CM2 study, implanting its neuromodulation device in chronic migraine patients across the US and Australia to assess therapeutic effects.
QurAlis' QRL-201, designed to restore STMN2 expression, enters the dose range-finding phase of its Phase 1 ANQUR trial after successful dose escalation.